Articles tagged with T Lymphocytes
Researchers have successfully treated patients with advanced CD19-positive hematologic malignancies using CAR T cells, achieving complete remission in some cases. The study used the Sleeping Beauty non-viral transduction system to modify T cells, demonstrating further promise in treating lymphoid malignancies.
New immunotherapy treatments aim to enable the body's natural defenses to recognize and destroy malignant cells. Studies present promising early data that encourage long-term outcomes among patients who have not responded to other therapies, including checkpoint inhibitors and drugs targeting the PD-1 pathway.
In a groundbreaking clinical trial, nivolumab achieved complete or partial remission in 87% of patients with resistant Hodgkin lymphoma. The treatment targets the immune system, reactivating T cells to attack cancer cells.
Scientists at VCU Massey Cancer Center use computer modeling to predict which patients are at greatest risk for developing GVHD after stem cell transplantation. The researchers found that minor histocompatibility antigens play a crucial role in shaping the development of T-cell clonal families.
A new study reveals that targeting specific immune cells in the gut can reduce the risk of HIV transmission by 2.7 times. The findings suggest that existing drugs for inflammatory bowel diseases could be effective in treating or preventing HIV infection.
Research shows that starting HIV therapy soon after infection significantly reduces the risk of developing AIDS and improves immune function, particularly when treatment is initiated within 12 months of seroconversion. A normal CD4+ T-cell count above 800 cells per cubic millimeter is crucial for reconstituting immune-fighting cells.
A new study suggests that starting HIV treatment within a year of seroconversion can improve immune health by increasing CD4+ T-cell count. Researchers found that an HIV-infected person's CD4+ T-cell count is more likely to return to normal if treatment starts within a year and at a CD4+ T-cell count of 500 or more.
A new study by University of California, San Francisco researchers has discovered a rare population of immune cells associated with less severe cancer outcomes in humans. These 'good' cells, known as antigen-presenting CD103+ dendritic cells, are found in most tumors and may hold therapeutic potential.
Researchers at the University of California, San Diego School of Medicine have discovered that T-cells are activated by a pain receptor called TRPV1 channel. The study shows that this receptor helps regulate intestinal inflammation in mice, suggesting a potential new target for treating certain autoimmune disorders.
Researchers have identified a better measure of predicting cancer neoepitopes, which are specific protein sequences recognized by immune cells. This new approach has the potential to improve current methods for generating anticancer vaccines, increasing their effectiveness in combating cancer.
Research suggests that newborn babies have a strong immune system, triggered by T cells producing IL8, which activates neutrophils to fight infections. This finding may lead to future treatments aimed at boosting neonatal immunity in intensive care settings.
Patients with common variable immunodeficiency (CVID) experience recurrent bacterial infections due to exhausted T cells expressing inhibitory protein PD-1. Rejuvenating these cells through blocking PD-1 may offer protection against bacterial infections, suggesting a potential therapeutic strategy.
High levels of T-bet in CD8+ T cells are prevalent in individuals who successfully fight off hepatitis infections. The protein is linked to the production of antiviral molecules like interferon and the ability of CD8+ T cells to multiply in response to the virus.
Researchers have grown a fully functional thymus organ from transplanted laboratory-created cells in a living animal. This breakthrough discovery could lead to new treatments for people with weakened immune systems and may also offer a way of making patient-matched T cells for cell therapies.
Researchers found that TIM-family proteins can block the release of HIV and Ebola viruses by attaching to lipids on the surface of viral particles. This discovery provides a potential approach to slow virus production and replication.
Researchers at Temple University have successfully eliminated the HIV virus from cultured human cells using a molecular tool that targets and deletes the viral genome. The approach has potential as both a treatment and prevention method for HIV, offering hope for a cure for AIDS.
Researchers at Monash and Melbourne Universities have determined the basic structure of one of two known families of deceptive proteins used by viruses. The discovery is an important step towards producing better vaccines and drugs to fight viral disease.
Researchers identify a novel mode of cancer cell recognition by the immune system, opening up new possibilities for leukemia immunotherapy. A specific group of immune cells, called mLPA-specific T-cells, recognize and destroy leukemia cells triggered by the newly identified lipids.
Four Monash researchers have been awarded top prizes in the NHMRC's Research Excellence Awards for their groundbreaking work on MAIT cells, infection prevention, and population health. Associate Professor Allen Cheng and Associate Professor Terry Haines will lead projects to develop new treatments and improve healthcare services.
A new T cell therapy has been developed to protect immunodeficient patients from infections. The treatment involves transferring a few immune cells, which are then used to fight off specific pathogens, and has shown great potential in clinical trials.
A new study by Prof. Gennaro De Libero and his team at the University of Basel identifies a lipid molecule, methyl-lysophosphatidic acid (mLPA), that stimulates specific T cells to kill leukemia cells. This breakthrough discovery offers new avenues for non-invasive cancer immunotherapies.
Researchers at the University of Cincinnati have discovered a therapy that reverses new onset Type 1 diabetes in mouse models. The treatment targets the innate immune system and boosts activity of TLR4, preserving insulin-producing beta cells. This approach may hold promise for treating Type 1 diabetes in humans.
A study using Sequenta's LymphoSIGHT platform reveals that patients with longer survival have lower numbers of T cell clones that decrease in frequency after treatment. This association holds for both prostate cancer and melanoma patients, suggesting that immune repertoire sequencing could predict clinical benefit of immunotherapies.
Researchers have discovered a common rulebook for the immune system's T cells, enabling faster identification of antigens and potential treatments. This breakthrough could lead to improved understanding of autoimmune diseases like diabetes and multiple sclerosis.
Researchers at University of California - San Francisco have developed a new cancer immunotherapy that manipulates the thymus gland to alter its activity, allowing specialized immune cells to battle cancer cells. The treatment has been shown to be effective in treating deadly melanoma skin cancers in mice.
Researchers have discovered a synthetic molecule that inhibits T-cell signaling in the lungs, preventing asthma symptoms such as inflammation and airway constriction. The molecule shows promise for treating asthma, a chronic disease affecting over 25 million Americans.
Researchers found that people infected with HIV who have low cholesterol levels in their immune cells experience slower disease progression. The study suggests that this inherited trait may affect the body's ability to transmit the virus to other cells, leading to a slower progression of AIDS.
Researchers propose that Parkinson's disease could be linked to the immune system attacking healthy neurons, potentially leading to new treatments. The study found that certain neurons display antigens, which are recognized by T-cells and can kill them, raising hopes for a new understanding of the disease.
Researchers at Case Western Reserve University have developed a new method to isolate single immune cells from the mouth, allowing them to study how these cells fight diseases. The method successfully isolated over 94% of the cells, enabling researchers to gain insights into treating oral cancers and other health issues.
Researchers discovered that mechanical forces play a crucial role in T-cell recognition and signaling. The study found that the magnitude, duration, frequency, and timing of force application determine the outcome of an interaction between an antigen and a TCR. This new understanding adds another dimension to interactions with T-cells.
Researchers have identified a precise biochemical key that activates immune cells called MAITs, which defend against bacterial and fungal invaders. The breakthrough has potential applications in treating inflammatory bowel disease, peptic ulcers, and tuberculosis.
Researchers have discovered the biochemical trigger that wakes up immune cells, allowing them to target invading bacteria and fungi. This breakthrough could lead to new treatments for inflammatory bowel disease, peptic ulcers, and even TB.
The HSV-2 vaccine candidate, GEN-003, generated highly significant reductions in clinical lesion days and rate of viral shedding at six months after the final vaccine dose. The study showed a 72% reduction in lesion days and a 50% reduction in mean viral shedding from baseline.
Researchers found that blocking a specific immune cell mediator can greatly reduce brain damage after a stroke. The study showed that treating mice with a compound that blocks IL-21 significantly reduced stroke damage and improved outcomes.
Researchers genetically engineered T cells to resist HIV infection by inducing the CCR5-delta-32 mutation. The study showed promising results with reduced viral loads and persistent modified cells in patients.
Researchers analyzed T cell receptor sequences to understand immune system reconstitution following high-dose immunosuppression. CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns, with dominant clones expanded or undetectable at 12 months post-transplant.
A neurotensin conjugate has shown effective transportation across the blood brain barrier and dose-dependent pain relief in animal models. In contrast, hematopoietic stem cell transplantation has been found to impact T cell repertoire in multiple sclerosis patients, with diverse repertoires associated with better treatment responses.
Researchers have found that during active rejection episodes, many to most of the immune cells involved are of donor origin. This discovery provides new insights into the rejection process, suggesting that transplanted faces carry their own army of immune cells that may defend against rejecting recipient cells.
Engineered immune cells, called CARTmeso cells, have shown antitumor activity in two patients with advanced cancers that failed prior treatments. The temporary CARs are safe and trigger a response against the patient's own tumor, providing a new tool for solid cancer therapy.
A study at Johns Hopkins Medicine found that vitamin D appears to block damage-causing immune cells from migrating to the central nervous system, potentially preventing or easing symptoms of multiple sclerosis. The research suggests that vitamin D may slow a process allowing T cells to grab onto blood vessel walls.
Researchers from Penn Medicine report promising results from a study of 59 leukemia patients treated with cell therapy, achieving high response rates and durable remissions. The treatment, known as CTL019, has shown long-term effectiveness in patients with both acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
A personalized cell therapy reprograms a patient's immune system to eliminate tumors in blood, showing complete responses in 89% of patients with high-risk ALL. The treatment has also been shown to persist in circulation and prevent cancer recurrence.
Researchers found a protein, Sprouty-2, that causes loss of function in immune cells combatting HIV, but disabling it restored their ability to fight the virus. Disabling both Sprouty-2 and PD-1 in exhausted T cells reversed exhaustion completely.
Scientists have engineered B cells to synthesize and deliver microRNA, a non-coding RNA that can be used to introduce or inhibit specific proteins. This achievement may lead to new therapeutic applications, including vaccination and cancer treatment.
Researchers found that two p53 isoforms, Δ133p53 and p53β, play a crucial role in regulating senescence. The study suggests that altering the ratio of these isoforms may be an effective therapeutic strategy for treating immunosenescence disorders.
A new study suggests that pregnant women with hepatitis C can pass a more replicative viral strain to their newborns, which increases the risk of persistent infection. This occurs due to immune changes during pregnancy, which impair CD8+ T-cell function and allow the virus to thrive.
Researchers at Howard Hughes Medical Institute discovered that the pool of inactive HIV viruses in a patient's body is larger than expected, with some retaining the ability to become active even after treatment. This finding suggests that targeting the inactive viruses, known as proviruses, is crucial for achieving a complete cure.
A new UCLA study reveals that cocaine makes quiescent CD4 T cells susceptible to HIV infection. Chronic cocaine exposure can increase the pool of infected cells with a higher viral reservoir, posing significant implications for HIV-positive individuals who abuse stimulants.
New research published in the Journal of Leukocyte Biology suggests that cocaine makes quiescent CD4 T cells more susceptible to HIV infection. The study found significant infection and new virus production in treated cells compared to untreated ones.
Researchers at Scripps Research Institute discovered a critical role of dendritic epidermal T cells in producing interleukin-17A to promote wound healing. The study found that these skin-resident immune cells function as 'first responders' to skin injuries by producing IL-17A, which wards off infection and promotes wound healing.
Researchers used the 2009 pandemic to study why some people resisted severe illness, finding that those with more virus-killing immune cells were protected. A vaccine targeting these cells could prevent flu viruses from causing serious disease.
A new vaccine has shown promise in boosting the immune system's ability to attack leukemia cells in post-transplant patients. The personalized tumor vaccine, which includes the patient's own irradiated leukemia cells combined with an immune stimulant, has been shown to induce a strong and selective immune response.
A study led by researchers at Children's Hospital of Pittsburgh found that immune cells in children with chronic arthritis show signs of premature aging. This discovery could lead to the development of cell-targeted therapies to prevent premature immune aging.
A gene mutation disrupts immune cell activity, causing liver attacks in autoimmune hepatitis. Researchers create model to study treatment targets and therapies.
Researchers have developed an assay to quantify structural avidity in living T cells, a key predictor of success in adoptive transfer therapies. The technology offers advantages over previous methods, including simplicity, non-invasive measurement, and quantitative assessment of binding strength.
A recent study published in Nature reveals that septins play a crucial role in activating the calcium channel on T cell surfaces, allowing them to fight disease. This discovery provides new insights into the intricate pathways involved in turning on T cells and could lead to the development of more targeted drugs.
Researchers have identified an immune protein called CD52 that can suppress the immune response and prevent or reverse type 1 diabetes. This discovery has wider implications for treating autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
A new study reveals distinct characteristics between inducible and natural IL17-producing T cells, with different signals required for cytokine production. The findings suggest a specific role of Akt protein complex in regulating cytokine production by these cell types.
Researchers have identified CD8αα+ T cells, which reside long-term in the genital skin and mucosa, suppressing recurring outbreaks of genital herpes. These immune cells play a crucial role in preventing reactivations of the virus, making them a potential target for vaccine development.
Researchers have identified a new type of immune cell in the skin that plays a role in fighting parasitic invaders and could be linked to eczema. The discovery sheds light on the causes of allergic skin diseases and offers new hope for treating hundreds of millions of people worldwide.